银杏达莫联合依达拉奉治疗急性脑梗塞临床疗效及安全性研究.docVIP

银杏达莫联合依达拉奉治疗急性脑梗塞临床疗效及安全性研究 　　[摘要] 目的 分析研究银杏达莫联合依达拉奉治疗急性脑梗塞的临床疗效及安全性。 方法 整群选取于2014年1月―2015年5月来院治疗的急性脑梗塞患者79例作为研究对象，按治疗方法的不同分为对照组（n=38）和观察组（n=41），对照组给予单纯依达拉奉治疗，观察组给予银杏达莫联合依达拉奉治疗，采用美国国立卫生研究院卒中量表（NIHSS）对患者的各项指标进行评定，观察对比两组患者的临床效果及不良反应发生情况。结果 观察组的有效率为95.12%，对照组的有效率为78.95%，差异有统计学意义（P0.05）。 结论 急性脑梗塞采取银杏达莫联合依达拉奉治疗的临床效果优于单纯依达拉奉治疗，且安全性好，值得在临床中推广使用。 　　[关键词] 急性脑梗塞；银杏达莫；依达拉奉；安全性 　　[中图分类号] R74 [文献标识码] A [文章编号] 1674-0742（2015）10（a）-0158-03 　　Study on the Clinical Efficacy and Safety of Yinxingdamo Injection Combined with Edaravone in Treatment of Acute Cerebral Infarction 　　SUN Yan-fen 　　Department of pharmacy， Danyang Hospital of Traditional Chinese Medicine， Danyang， Jiangsu Province，212300 China 　　[Abstract] Objective To analyze clinical effect and safety of Yinxingdamo injection combined with edaravone in treatment of acute cerebral infarction. Methods A total of on 5 January 2014 to 2015 to hospital treatment of patients with acute cerebral infarction in 79 cases as the research object， according to the different treatment methods as control group （38 cases） and observation group （n=41）， the control group was treated with edaravone treatment， observation group give ginkgo leaf extract and dipyridamole injection combined with edaravone， by the United States National Institutes of Health Stroke Scale （NIHSS） for patients with various indicators of evaluation， to observe the clinical effects and side effects were compared between the two groups occurred. Results In the observation group， the efficiency was 95.12%. In the control group effective 78.95%， the difference was statistically significant （P0.05）. Conclusion Acute cerebral infarction by edaravone combined with ginkgo leaf extract and dipyridamole in the treatment of clinical effect is better than pure edaravone treatment and safety of good， it is worth in clinical application. 　　[Key words] Acute cerebral infarction； Ginkgo dipyridamole； Edaravone； Safety 　　急性脑梗塞是临床上常见病、多发病，是指因各种原因导致局部脑组织缺血、缺氧而引起的脑血管疾病，具有发病率高、死